TAP2 Gene Expression Measurement for Infection Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical diagnostic tests lack the ability to identify patients at high risk for healthcare-associated infections, which are prevalent in medical facilities and contribute to increased morbidity, mortality, and healthcare costs.
Innovation Solution
A method involving the measurement of TAP2 gene expression in biological samples from patients to determine the risk of developing healthcare-associated infections, potentially combined with the expression analysis of other genes involved in immune response and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current clinical diagnostic tests are used, then general patient monitoring is maintained, but the ability to identify patients at high risk for healthcare-associated infections is lacking
Solution Approach 1:
The patent changes the measurement parameter from general clinical indicators to specific gene expression levels (TAP2, HLA-DMA, HLA-DPB1) to accurately identify patients at high risk for healthcare-associated infections. This molecular parameter change enables precise risk stratification that traditional clinical tests cannot achieve.
Solution Approach 2:
The patent introduces gene expression analysis as an intermediary diagnostic tool between general patient monitoring and specific infection risk prediction. By measuring TAP2 and other gene expressions, the system mediates the connection between routine clinical care and targeted prevention strategies for high-risk patients.
2Reliability
If early identification of high-risk patients is implemented, then mortality and healthcare costs are reduced, but no clinical in vitro diagnostic test currently exists
Solution Approach 1:
The patent segments the diagnostic approach by focusing on specific gene expression markers (TAP2, HLA-DMA, HLA-DPB1) rather than attempting comprehensive multi-parameter analysis. This segmentation makes the diagnostic test feasible and manufacturable while maintaining high reliability in identifying high-risk patients.
Solution Approach 2:
The patent replaces complex mechanical or procedural diagnostic systems with a molecular biology-based in vitro test measuring gene expression levels. This substitution simplifies the diagnostic process, making it easier to manufacture and implement clinically while improving reliability in risk prediction.
3Reliability
If comprehensive infection control programs are implemented, then serious infections are reduced, but compliance is complicated particularly in low- or middle-income countries
Solution Approach 1:
The patent enables preliminary identification of high-risk patients through gene expression testing before infections occur. This allows healthcare facilities to implement targeted prevention measures only for identified high-risk patients, simplifying compliance by focusing resources on those who need them most rather than requiring universal complex protocols.
Solution Approach 2:
The patent changes the approach from monitoring multiple complex infection control parameters to measuring specific gene expression levels. This parameter change simplifies the diagnostic process and makes infection risk assessment more feasible in resource-limited settings while maintaining high effectiveness in preventing serious infections.
Data Source
AI summary
An in vitro or ex vivo method for determining the risk of incidence of a healthcare-associated infection includes a step of measuring the expression of TAP2 in a biological sample from said patient.